We found that the highest anti-MM activity was achieved in resistant cell lines when VTX was combined with both MCL-1 and BCL-XL inhibitors, suggesting that even reduced BCL-2 is still significantly involved in survival, and BCL-XL and MCL-1 upregulation cannot sufficiently offset its loss or reduced function. The gene discussed is BCL2; the disease is Miyoshi myopathy.